Capstone Investment Advisors
MTNB icon

Capstone Investment Advisors’s Matinas BioPharma MTNB Stock Holding History

Capstone Investment Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-258
Closed -$14K – 1814
2021
Q1 		$14K Sell
258
-1,182
-82% -$79.3K ﹤0.01% 1630
2020
Q4 		$98K Buy
+1,440
New +$66.7K ﹤0.01% 1560

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Capstone Investment Advisors's MTNB Position: Q2 2021 in Review

Capstone Investment Advisors sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 258 shares — an estimated $14K sold.

Capstone Investment Advisors first reported a position in MTNB in Q4 2020 and held it in 2 quarters. The position peaked at $98K in Q4 2020. 67 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

  • Capstone Investment Advisors reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 258 Matinas BioPharma shares in Q2 2021, an estimated $14K.
  • Capstone Investment Advisors first reported a position in Matinas BioPharma in Q4 2020 and held it in 2 quarters.
  • Capstone Investment Advisors's Matinas BioPharma position peaked at $98K in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on Capstone Investment Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.